Overview
Mengyao Li practices practicing medicine in Shaoxing, China.
Their clinical expertise encompasses Neurofibromatosis Type 2 (NF2), Renal Cell Carcinoma (RCC), Bladder Cancer, and Urothelial Cancer.
They are actively involved in clinical research, co-authoring 11 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Mengyao Li
Is Mengyao Li a top-rated expert for Neurofibromatosis Type 2 (NF2)?
MediFind is an objective health platform that identifies experts based on real-world data. Mengyao Li is classified as an Experienced expert for Neurofibromatosis Type 2 (NF2), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Mengyao Li participate in research or clinical trials?
Yes. Mengyao Li has published 11 articles and abstracts on conditions like Neurofibromatosis Type 2 (NF2). You can view a list of Mengyao Li's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Bladder CancerLi isExperienced. Learn about Bladder Cancer.
- Lung MetastasesLi isExperienced. Learn about Lung Metastases.
- Neurofibromatosis Type 2 (NF2)
- Renal Cell Carcinoma (RCC)
- Urothelial CancerLi isExperienced. Learn about Urothelial Cancer.